Phase 3 Eczema Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who understand and are willing to sign a consent form, and who are able to attend regular visits and follow the study plan as required.
- People aged 18 to 75 years old at the time of signing the consent form.
- People who have been diagnosed with atopic dermatitis (a type of eczema) using a recognised diagnostic checklist, and who have had symptoms for at least one year before the study start date.
- People whose atopic dermatitis is rated as moderately severe by the study doctor, based on specific scoring tools measuring the affected skin area and severity (confirm with trial site for exact score thresholds).
- People who have tried a cream or ointment treatment for their atopic dermatitis within the past year, but either did not respond well enough to it or could not tolerate it.
Who may not be able to join:
- People who have difficulty swallowing tablets, persistent nausea or vomiting, or a digestive condition (such as Crohn's disease, ulcerative colitis, or short bowel syndrome) that may interfere with the body absorbing the study drug.
- People who have, or have had, a blood or lymph system cancer, any cancer of lymph tissue, swollen lymph nodes or an enlarged spleen, or any other cancer within the past five years (with some exceptions for certain fully removed or non-spreading skin cancers or cervical or thyroid conditions — confirm with trial site).
- People who have previously had a blood clot in a vein or artery (such as a deep vein thrombosis or pulmonary embolism), or who are otherwise considered at high risk of developing blood clots.
- People who have had a herpes virus infection in the past month, have had shingles or herpes simplex infections more than once, have had a widespread herpes infection, or where an active herpes infection cannot be ruled out at the time of screening.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: qianjin Lu, Chinese Academy of Medical Sciences Hospital of Skin Disease
Phone: 15358160458
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Proportion of subjects achieving at least a 75% reduction in Eczema Area and Severity Index (EASI 75) from Baseline at Week 16
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.